Literature DB >> 9310510

Otitis media-related antibiotic prescribing patterns, outcomes, and expenditures in a pediatric medicaid population.

S Berman1, P J Byrns, J Bondy, P J Smith, D Lezotte.   

Abstract

BACKGROUND: Treatment of otitis media is the most frequent reason for administering antibiotics to children in the United States. However, only limited data are available on medical effectiveness of antibiotic prescribing patterns for otitis media and their associated expenditures or the factors that influence antibiotic prescribing.
METHODS: The study population consisted of 131 169 children during 1991 and 157 065 children during 1992 who were </=13 years of age and enrolled in Colorado's fee-for-service Medicaid program. Among these children, 5127 (1991) and 7254 (1992) were enrolled in the cohort treated for a "new" episode of acute otitis media. An analysis using this cohort was performed to document the antibiotics used to treat a new episode of acute otitis media, factors influencing antibiotic selection, and the short-term outcomes of therapy. An analysis using the entire Medicaid population was performed to document the annual use of antibiotics for otitis, the associated antibiotic expenditures, and factors influencing antibiotic selection.
RESULTS: In the cohort analysis, office-based physicians prescribed second- and third-generation cephalosporins more often than did physicians in other settings (17% vs 9.7% and 11.8%), whereas hospital clinics prescribed trimethoprim plus sulfamethoxazole more frequently than did office-based physicians (19.2% vs 7.1% and 10.9%). Family physicians prescribed second- and third-generation cephalosporins more often than did pediatricians (16.6% vs 12.3%) but trimethoprim plus sulfamethoxazole and erythromycin plus sulfisoxazole less often than did pediatricians (10.5% vs 17%). The average rate of prescribing a second course of antibiotics within 24 days after initial antibiotic treatment of a new acute otitis media episode was 11.6% when less expensive antibiotics (amoxicillin, trimethoprim plus sulfamethoxazole, or erythromycin plus sulfisoxazole) were prescribed, and 13.2% when more expensive antibiotics (cefaclor, amoxicillin plus clavulanate, or cefixime) were prescribed. The average adverse drug reaction rate was 5.9% when less expensive antibiotics were prescribed, compared with 6.1% when more expensive antibiotics were prescribed. In each of the two study years, amoxicillin accounted for almost half of the total antibiotic fills but only 9% to 10% of the expenditures. Low-cost antibiotics (amoxicillin, trimethoprim plus sulfamethoxazole, and erythromycin plus sulfisoxazole) were prescribed for 66% to 67% of the total fills and accounted for 21% of the total projected expenditures. More expensive antibiotics (cefaclor, cefixime, amoxicillin plus clavulanate) prescribed for 30% of the fills generated 76% to 77% of expenditures. Cefaclor, prescribed for 17% to 18% of the total fills, generated 43% to 45% of total antibiotic expenses.
CONCLUSIONS: The findings of this study document a preference for amoxicillin as the initial antibiotic for a new episode of acute otitis media. Although there was a wide variation in the selection of antibiotics to treat otitis, the more expensive antibiotics were not associated with better outcomes. This wide variation has important financial implications because of differences in antibiotic costs. Changes in prescribing patterns among initially uncomplicated children that reduce the use of high-cost antibiotics could reduce expenditures substantially without compromising short-term outcomes.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9310510     DOI: 10.1542/peds.100.4.585

Source DB:  PubMed          Journal:  Pediatrics        ISSN: 0031-4005            Impact factor:   7.124


  18 in total

1.  Children's health care issues: a continuing priority.

Authors:  D M Dougherty; L A Simpson; J M Eisenberg
Journal:  Health Serv Res       Date:  2000-10       Impact factor: 3.402

2.  Delayed antibiotic prescriptions for URTIs.

Authors:  Noah Ivers; Bruce Arroll; G Michael Allan
Journal:  Can Fam Physician       Date:  2011-11       Impact factor: 3.275

3.  Treatment cost effectiveness in acute otitis media: A watch-and-wait approach versus amoxicillin.

Authors:  Isabelle Gaboury; Kathryn Coyle; Douglas Coyle; Nicole Le Saux
Journal:  Paediatr Child Health       Date:  2010-09       Impact factor: 2.253

4.  Parental acceptability of the watchful waiting approach in pediatric acute otitis media.

Authors:  Arnon Broides; Olga Bereza; Noga Lavi-Givon; Yariv Fruchtman; Eli Gazala; Eugene Leibovitz
Journal:  World J Clin Pediatr       Date:  2016-05-08

Review 5.  Should newborns be screened for immunodeficiency?: lessons learned from infants with recurrent otitis media.

Authors:  Yesim Yilmaz-Demirdag
Journal:  Curr Allergy Asthma Rep       Date:  2011-12       Impact factor: 4.806

6.  Decrease in antibiotic use among children in the 1990s: not all antibiotics, not all children.

Authors:  Anita L Kozyrskyj; Anita G Carrie; Garey B Mazowita; Lisa M Lix; Terry P Klassen; Barbara J Law
Journal:  CMAJ       Date:  2004-07-20       Impact factor: 8.262

7.  Evidence-based prescribing of antibiotics for children: role of socioeconomic status and physician characteristics.

Authors:  Anita L Kozyrskyj; Matthew E Dahl; Dan G Chateau; Garey B Mazowita; Terry P Klassen; Barbara J Law
Journal:  CMAJ       Date:  2004-07-20       Impact factor: 8.262

8.  Otitis media in children with congenital immunodeficiencies.

Authors:  Simon Urschel
Journal:  Curr Allergy Asthma Rep       Date:  2010-11       Impact factor: 4.806

Review 9.  Practical considerations when treating children with antimicrobials in the outpatient setting.

Authors:  L N Werk; H Bauchner
Journal:  Drugs       Date:  1998-06       Impact factor: 9.546

10.  Antibiotic choices by paediatric residents and recently graduated paediatricians for typical infectious disease problems in children.

Authors:  Katharine Smart; Jean-Francois Lemay; James D Kellner
Journal:  Paediatr Child Health       Date:  2006-12       Impact factor: 2.253

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.